Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

Completed · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.

Key facts

Study ID: NCT05251259
Run by: AstraZeneca
People needed: 670
Starts: 2022-01-27
Expected to finish: 2026-01-07
Last updated by the study team: 2026-01-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Lead-in PK Cohort:
18 to 55 years of age inclusive at the time of signing the informed consent at screening Visit 1.
Bodyweight 50 to 120 kg (inclusive) and BMI 18 to 32 kg/m\^2 (inclusive) at screening Visit 1.
Documented asthma diagnosis ≥12 months prior to screening Visit 1.
Able to perform acceptable lung function testing for FEV1 according to American Thoracic Society / European Respiratory Society (ATS/ERS) 2019 acceptability criteria.
Morning pre- bronchodilator (BD) forced expiratory volume (FEV)1 ≥ 40% predicted at screening Visit 1 and Visit 2.
Treated with low dose inhaled corticosteroid plus long-acting β2-agonist (ICS-LABA) or medium-high dose ICS alone or in combination with LABA at a stable dose for at least 3 months prior to screening Visit 1. Also, treatment with additional asthma controller therapies (eg, LAMA) at a stable dose ≥ 3 months prior to screening Visit 1 is allowed.
Participant's influenza/pneumonia vaccination is up to date as per local guidelines prior to Visit 2.
General Inclusion Criteria for Part 1:
Body weight ≥ 40 kg and body mass index (BMI) < 35 kg/m\^2.
Documented history of ≥ 1 severe asthma exacerbation within 1 year prior to screening Visit 1.
Able to perform acceptable lung function testing for FEV1 according to ATS/ERS 2019 acceptability criteria.
Morning pre-BD FEV1 between ≥ 40% and ≤ 85% predicted at screening Visit 1 and Visit 3.
An Asthma Control Questionnaire (ACQ)-6 score ≥ 1.5 at screening Visit 1 and at Visit 3.

You may not qualify if…

A severe asthma exacerbation within 8 weeks of screening (visit 1) or within 12 weeks of randomisation (Visit 3).
A positive test result of an approved antigen test (confirmed by a positive RT-PCR test) or a positive RT-PCR test for SARS-CoV-2, the virus responsible for COVID-19, at screening Visit 1 or at Visit 2 for the PK Lead-in cohort. For Part 1 the testing will be done at Visit 3. Results from the mandatory tests at Visit 2 (PK Lead-in cohort) and Visit 3 (Part 1) must not be older than 48 hours and must be available before randomisation.
Participants with a significant COVID-19 illness within 6 months of enrolment.
Clinically important pulmonary disease other than asthma.
Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable.
Any clinically significant cardiac disease.
History of severe renal disease or history of creatinine clearance < 30 mL/min × m2 calculated using Cockcroft-Gault equation.
Severe hepatic impairment (Child-Pugh class C).
Previous hepatotoxicity related to zileuton or leukotriene receptor antagonist (LTRAs) (eg montelukast).
Participants with a recent history of, or who have a positive test for, infective hepatitis or unexplained jaundice, or participants who have been treated for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
Evidence of active tuberculosis (TB), either treated or untreated or latent TB.
Current or history of alcohol or drug abuse (including marijuana).
Current diagnosis of cancer, not including in-situ or non-melanoma skin cancer or other previous malignancies where curative therapy was completed at least 5 years prior to screening Visit 1.
Clinically important ongoing or previous psychiatric disease, especially suicidal behaviour, that in the opinion of the investigator might compromise the safety of the participant in the study.
Treatment with any serum creatinine-altering drugs within 1 month prior to screening Visit 1 including but not limited to amphotericin, cimetidine, clofibrate, dronedarone, ketoconazole, probenecid, ranolazine, trimethoprim, aminoglycosides, or cephalosporins.
Treatment with systemic corticosteroid use within 8 weeks (oral) or 12 weeks (intramuscular) before screening (Visit 1) or 12 weeks (oral) or 16 weeks (IM) before randomization (Visit 3).
Treatment with marketed biologics including benralizumab, mepolizumab, reslizumab, omalizumab, and dupilumab within 6 months of screening Visit 1 or 5 half-lives whichever is longer.
Treatment with 5-lipoxygenase inhibitors (eg zileuton or other 5-LO inhibiting supplements) within 6 weeks prior to Visit 0 and within 8 weeks prior to Visit 1).Treatment with LTRAs (eg, montelukast) within 2 weeks prior to Visit 0 and within 4 weeks prior to screening Visit 1.
Inhaled corticosteroid + fast-acting β2 agonist as a reliever (eg Symbicort or Fostair Maintenance and Reliever Treatment) is not allowed 15 days prior to screening Visit 1, during screening (Visit 1)/run-in and the treatment period and preferably 1 week after the last dose of study intervention.
Live or attenuated vaccines within 4 weeks of screening Visit 1.
Immunoglobulin or blood products within 4 weeks of screening Visit 1.
Treatment with Gemfibrozil within 4 weeks of screening Visit 1.
Any immunotherapy within 6 months of screening Visit 1, except for stable maintenance dose allergen-specific immunotherapy started at least 4 weeks prior to screening Visit 1 and expected to continue through to the end of the follow-up period.
Potent inducers/inhibitors of cytochrome P450 3A4 within 4 weeks of screening Visit 1.
Treatment with simvastatin, lovastatin, and atorvastatin at doses > 40 mg per day within 1 month prior to screening Visit 1. Treatment with sensitive cytochrome 3A substrates with narrow therapeutic window should be avoided from randomization to study drug.

Where it is running

Research Site — Niigata, Japan
Research Site — Osaka, Japan
Research Site — Osaka, Japan
Research Site — Sagamihara-shi, Japan
Research Site — Fountain Valley, California, United States
Research Site — CABA, Argentina
Research Site — Capital Federal, Argentina
Research Site — Ciudad Capital, Argentina
Research Site — Ciudad de Buenos Aire, Argentina
Research Site — Birmingham, Alabama, United States
Research Site — Sheffield, Alabama, United States
Research Site — Phoenix, Arizona, United States
Research Site — Tucson, Arizona, United States
Research Site — Little Rock, Arkansas, United States
Research Site — Bakersfield, California, United States
Research Site — Kyoto, Japan
Research Site — Huntington Beach, California, United States
Research Site — Los Angeles, California, United States
Research Site — Newport Beach, California, United States
Research Site — San Jose, California, United States
Research Site — Valencia, California, United States
Research Site — Colorado Springs, Colorado, United States
Research Site — Cutler Bay, Florida, United States
Research Site — Cutler Bay, Florida, United States
Research Site — Nakagun, Japan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.